Erlotinib is an EGFR tyrosine kinase inhibitor. It’s used to treat advanced, non-small cell lung cancer with an EGFR mutation. An adverse side effect of Erlotinib is the development of rashes on the face and back.

Key Points

  • Erlotinib
    • Mechanism
      • EGFR tyrosine kinase inhibitor
    • Clinical use
      • Non-small cell lung cancer
        • Advanced Non-small cell lung cancer with an EGFR mutation 
    • Adverse effects
      • Rash (nonspecific)